Activity of a Novel Cyclic Lipopeptide, CB-183,315, against Resistant Clostridium difficile and Other Gram-Positive Aerobic and Anaerobic Intestinal Pathogens

Antimicrobial Susceptibilities and Molecular Epidemiology of Clinical Isolates ofClostridium difficilein Taiwan

(2011) Yi-Chun Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species

(2011) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread

(2010) Archie CA Clements et al.   LANCET INFECTIOUS DISEASES

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

(2009) D.M. Citron et al.   ANAEROBE

In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993–2007 in Sweden

(2009) T. Norén et al.   CLINICAL MICROBIOLOGY AND INFECTION

Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004

(2009) S. K. Taori et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile

(2008) J. R. O'Connor et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile

(2008) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clostridium difficile Infections in a Canadian Tertiary Care Hospital before and during a Regional Epidemic Associated with the BI/NAP1/027 Strain

(2008) A.-C. Labbe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY